Acadia pharmaceuticals presents new dementia-related psychosis real-world outcomes data at psych congress 2021

San diego--(business wire)--acadia pharmaceuticals inc. (nasdaq: acad) announced today that three data presentations featuring new analyses of medicare claims data on dementia-related psychosis (drp) outcomes were presented at psych congress 2021, held virtually and in-person october 29-november 1, 2021 in san antonio, tx. the presentations demonstrate the suboptimal outcomes associated with the off-label use of currently available atypical antipsychotic treatments in managing dementia-related
ACAD Ratings Summary
ACAD Quant Ranking